Calquence (Acalabrutinib)

Acalabrutinib is a cancer medicine for some blood cancers, like chronic lymphocytic leukemia and mantle cell lymphoma. It is taken as a pill, usually twice a day. It works by blocking a protein that the cancer cells need to grow and survive.

Brand names:Calquence
Medication

What people taking Calquence (Acalabrutinib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Calquence (Acalabrutinib) for CLL (Chronic Lymphocytic Leukemia)?

NameHow it went

About Calquence (Acalabrutinib)

What It's For

Acalabrutinib, sold as Calquence, is a targeted cancer pill for adults with certain blood cancers that start in B cells, a type of white blood cell. Its main use is chronic lymphocytic leukemia (CLL), a usually slow-growing cancer in which the bone marrow makes large numbers of abnormal lymphocytes. Small lymphocytic lymphoma (SLL) is the same disease under another name, and the approval covers both. For CLL, acalabrutinib can be taken on its own, whether or not the disease has been treated before. People starting their first CLL treatment have two other options: combining it with obinutuzumab, an antibody given by infusion that attaches to B cells and helps the immune system destroy them, or with venetoclax, another targeted cancer pill, as a fixed course of a little over a year rather than open-ended treatment. It also treats mantle cell lymphoma (MCL), a less common lymphoma. Adults whose MCL has returned or not responded after at least one earlier treatment can take acalabrutinib on its own. Adults with newly diagnosed MCL who are not candidates for a stem cell transplant using their own cells can take it together with the chemotherapy drug bendamustine and the antibody rituximab. Acalabrutinib belongs to a group of medicines called Bruton tyrosine kinase (BTK) inhibitors. Ibrutinib (Imbruvica) was the first of them. Acalabrutinib was designed to act more selectively, and in a head-to-head trial in people with previously treated, higher-risk CLL it held the disease in check for as long as ibrutinib while causing less atrial fibrillation, an irregular heart rhythm, and fewer people stopped because of side effects.

How It Works

B cells depend on a chain of internal signals to grow, multiply, move around the body and settle in places such as the lymph nodes and bone marrow. Many of those signals pass through the enzyme BTK. Cancerous B cells in CLL and mantle cell lymphoma rely heavily on this pathway. Acalabrutinib binds tightly to BTK and switches it off, cutting the signals the cancer cells use to multiply and survive. It does not wipe out the cancer at once. For most people it works by keeping the disease under control for as long as it is taken, which is why it is usually a continuous treatment rather than a short course.

Dosage & Administration

Calquence comes as a 100 mg tablet taken twice a day, about 12 hours apart, with or without food. The tablet should be swallowed whole with a glass of water and not chewed, crushed, dissolved or cut. Calquence was first sold as a capsule, which has its own instructions. Capsules and tablets should not be swapped without the prescriber, partly because the capsule is affected by stomach-acid medicines in a way the tablet is not. For most uses, treatment continues as long as the cancer stays controlled and side effects remain manageable. The exception is the venetoclax combination for previously untreated CLL: that plan is a fixed course of 14 four-week cycles. When acalabrutinib is combined with obinutuzumab, or with bendamustine and rituximab, those medicines are given as infusions on their own schedule. A dose that is less than 3 hours late can still be taken. After 3 hours, skip it and take the next dose at the usual time, without taking extra to make up for it. The prescriber may pause treatment, lower the dose or cut it to once a day if side effects build up or another medicine interferes with it.

Side Effects

The most common side effects are colds and other upper respiratory infections, diarrhea, headache, and muscle or joint pain, each affecting roughly a third of people in clinical trials. Blood tests often show low white blood cell or platelet counts, which is one reason counts are checked regularly. Infection is the most important serious risk. Pneumonia and less common infections that take advantage of a weakened immune system have occurred, and some have been fatal. Fever, chills or flu-like symptoms should be reported to the care team right away rather than waited out. People at higher risk may be given medicines to help prevent certain infections. Bleeding can range from easy bruising to serious bleeding. Black or bloody stools, pink or brown urine, vomiting blood or material that looks like coffee grounds, or coughing up blood should be reported right away. Bleeding that will not stop, or sudden confusion, a change in speech or a severe headache that does not go away, which can signal bleeding in the brain, needs emergency care. Heart rhythm problems, mainly atrial fibrillation, can develop, especially in people with heart disease, high blood pressure, earlier rhythm problems or an active infection. A fast or irregular heartbeat, dizziness, feeling faint, chest discomfort or shortness of breath should be reported right away. Liver injury is uncommon but can be severe; stomach pain or discomfort, dark urine or yellowing of the skin calls for prompt contact with the care team. New cancers have developed in some people taking acalabrutinib, most often non-melanoma skin cancers. Sun protection and regular skin checks are part of treatment.

Interactions & Warnings

Many medicines change how much acalabrutinib reaches the bloodstream, because a liver enzyme called CYP3A breaks it down. Strong blockers of that enzyme, such as the antifungal itraconazole, can raise levels enough to increase side effects, so they are avoided, or acalabrutinib is paused during a short course. Moderate blockers, such as the antibiotic erythromycin, the antifungal fluconazole and the heart medicine diltiazem, call for a lower dose. Strong enzyme boosters, such as rifampin (an antibiotic used for tuberculosis), can lower levels enough to weaken treatment, so they are also avoided when possible. Over-the-counter medicines, vitamins and herbal products can matter too, so the care team and pharmacist should see a complete list. Blood thinners and antiplatelet medicines add to the bleeding risk. They are sometimes still necessary, so the trade-off is weighed with the prescriber. Acalabrutinib may also be paused for several days before and after surgery or a dental procedure, so every surgeon and dentist should know about it. Based on animal studies, acalabrutinib may harm a developing baby and cause problems during labor. A pregnancy test may be done before starting, and people who could become pregnant should use effective birth control during treatment and for 1 week after the last dose. Breastfeeding is not recommended during treatment or for 2 weeks afterward. People with liver disease (including past hepatitis B), earlier heart rhythm problems or a bleeding disorder should make sure the prescriber knows, since these affect monitoring and, for severe liver disease, whether acalabrutinib should be used at all.

What to Expect

Acalabrutinib is usually a long-term treatment, continued for as long as it keeps the cancer under control and side effects stay manageable. In the main trial in previously untreated CLL, acalabrutinib, alone or with obinutuzumab, was compared with the older combination of chlorambucil chemotherapy and obinutuzumab. By the main analysis, about half of the people in the chemotherapy group had seen their disease worsen or had died, compared with about 1 in 7 taking acalabrutinib alone and fewer than 1 in 10 taking it with obinutuzumab. Responses still vary, and the care team tracks progress through blood counts, physical exams and sometimes scans. Expect regular visits with blood tests for blood counts and liver function, plus periodic skin checks. Many side effects can be handled by pausing treatment or adjusting the dose rather than stopping for good, so it is worth reporting problems instead of skipping doses on your own. The fixed-length venetoclax combination is the exception to long-term use: it ends after its planned course, and follow-up continues afterward.

Questions to Ask Your Doctor

  1. 1.Why is acalabrutinib a good fit for my type of CLL or lymphoma, compared with other BTK inhibitors, a fixed-length combination or chemotherapy-based treatment?
  2. 2.Will I take it on its own or with another medicine, and is the plan to continue indefinitely or for a set time?
  3. 3.Which of my current medicines, including blood thinners, antifungals, antibiotics and supplements, need to be changed or checked?
  4. 4.How often will my blood counts, liver tests and skin be checked, and which symptoms should prompt a call to you?
  5. 5.How should acalabrutinib be handled before surgery or dental work, and who decides when to pause and restart it?

Last reviewed • Oct 2026

Educational content, not medical advice.